EUVIMEDEUVIMED entdecken
Open Access

Safety and Effectiveness of Apixaban versus Warfarin in Peritoneal Dialysis Patients with Newly Diagnosed Nonvalvular Atrial Fibrillation

Mingyue He, Kevin F Erickson, Hania Kassem, Maria E Montez-Rath, Tara I Chang, Wolfgang C Winkelmayer, Jingbo Niu

American Journal of Nephrology · 07.07.2026 · 1-13

DOI: 10.1159/000553428 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Nephrology, online erschienen am 07.07.2026. Verfasst von Mingyue He und 6 weiteren Autor:innen. Beteiligte Einrichtung: Section of Nephrology, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Apixaban reduces thromboembolic events, bleeding, and mortality compared with warfarin in patients with nonvalvular atrial fibrillation (NVAF). However, evidence in patients with kidney failure (KF) receiving peritoneal dialysis (PD) is limited. We evaluated the safety and effectiveness of apixaban versus warfarin in this population.

Methods

Using the US Renal Data System, we identified Medicare beneficiaries on PD with newly diagnosed NVAF (2014–2019) who had no prior oral anticoagulation (OAC) use. We included patients initiating apixaban or warfarin within 30 days after NVAF diagnosis. After propensity matching, we estimated the hazard ratios for thromboembolic events, bleeding events, and mortality using Cox models accounting for competing risks, where applicable, and using both intent-to-treat and as-treated (AT) approaches.

Results

Among 6,571 OAC-naive PD patients with newly diagnosed NVAF, 334 initiated apixaban and 717 initiated warfarin within 30 days. After 1:1 propensity matching, all observed characteristics of 330 apixaban and 330 warfarin users were balanced. The median CHA2DS2-VASc score was 4 (IQR 3–5). In intent-to-treat analyses, hazards of ischemic stroke (hazard ratio [HR] = 0.92; 95% CI: 0.42–2.01) and the composite of other thromboembolic outcomes with cardiovascular death (HR = 0.90; 95% CI: 0.66–1.22) did not differ between groups. The hazards of clinically important bleeding (HR = 0.81; 95% CI: 0.62–1.07), major bleeding, intracranial hemorrhage, and all-cause mortality also did not differ between groups. Findings were consistent in AT analyses.

Conclusion

Among PD patients with newly diagnosed NVAF, we observed no statistically significant differences between apixaban and warfarin for effectiveness or bleeding outcomes. Given the challenges of warfarin management in KF, apixaban may represent a more practical option when anticoagulation is pursued.

Schlagwörter

Stichwörter der Autor:innen

ApixabanAtrial fibrillationKidney failurePeritoneal dialysisWarfarin

Autor:innen und Institutionen

  • Section of Nephrology, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
  • Division of Nephrology, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.
  • Section of Nephrology, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA, winkelma@bcm.edu.

Förderung

  • NIDDK NIH HHS

Zitieren

APA

He, M., Erickson, K. F., Kassem, H., Montez-Rath, M. E., Chang, T. I., Winkelmayer, W. C., & Niu, J. (2026). Safety and Effectiveness of Apixaban versus Warfarin in Peritoneal Dialysis Patients with Newly Diagnosed Nonvalvular Atrial Fibrillation. American Journal of Nephrology, 1-13. https://doi.org/10.1159/000553428

Vancouver

He M, Erickson KF, Kassem H, Montez-Rath ME, Chang TI, Winkelmayer WC, et al. Safety and Effectiveness of Apixaban versus Warfarin in Peritoneal Dialysis Patients with Newly Diagnosed Nonvalvular Atrial Fibrillation. American Journal of Nephrology. 2026:1-13. doi:10.1159/000553428

BibTeX
@article{He2026,
  author = {He, Mingyue and Erickson, Kevin F and Kassem, Hania and Montez-Rath, Maria E and Chang, Tara I and Winkelmayer, Wolfgang C and Niu, Jingbo},
  title = {Safety and Effectiveness of Apixaban versus Warfarin in Peritoneal Dialysis Patients with Newly Diagnosed Nonvalvular Atrial Fibrillation},
  journal = {American Journal of Nephrology},
  year = {2026},
  pages = {1--13},
  doi = {10.1159/000553428}
}
Kostenlos starten →